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Studies of retinoids in the prevention and 
treatment of cancer 
Frank L. Meyskens, Jr., M.D. 
Tucson, AZ 
Investigation of retinoids for anticancer activity in humans, either in 
the chemopreventive or treatment mode, has been little studied. We 
summarize here our ongoing investigations in four different areas: (1) 
secondary prevention of cervical dysplasia with topical application of 
all-trans-retinoic acid; (2) adjuvant reatment of resected high-risk 
stage I and II malignant melanoma with bacille Calmette Gu~rin 
(BCG) plus or minus oral vitamin A; (3) topical vitamin A acid 
therapy for cutaneous metastatic melanoma; and (4) oral isotretinoin 
as an anticancer agent. (J AM AChD DERMATOL 6:824-827, 1982.) 
A considerable volume of information has been 
presented at this workshop which substantiates the 
therapeutic effect of synthetic retinoids on kera- 
tinizing disorders, acne, and basal cell epithe- 
liomas. Extensive data in animals indicate that 
retinoids can suppress the phenotypic expression 
of  epithelial malignancies, whether initiated by 
chemical or physical carcinogens. 1,2 Additionally, 
retinoids exert an antiproliferative effect against 
many normal and cultured cells a and in some 
instances promote differentiation, 4-6 a pheno- 
menon best studied in murine 4 and human 5mela- 
noma and teratocarcinoma 6 cells. Investigations in
Europe have also indicated that retinoids can in- 
hibit the local growth of squamous cell malignan- 
cies of the skin. 7 We report here investigations 
which we have performed with retinoids in several 
different areas of clinical oncology. Four investi- 
gations will be presented and include: 
1. Secondary prevention of cervical dysplasia with 
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topical application of all-trans-retinoic acid (tre- 
tinoin) via a mechanical delivery system 
2. Adjuvant reatment of resected high-risk stage I
and stage II malignant melanoma with bacille 
Calmette Gurrin (BCG) plus or minus oral vita- 
min A palmitate 
3, Topical tretinoin therapy for cutaneous metastatic 
melanoma 
4. Oral 13-cis-retinoic acid (isotretinoin) as an anti- 
cancer agent. 
Secondary prevention of cervical neoplasia 
with topical application of tretinoin 
Vitamin A deficiency has long been known to 
be a cause of reversible epithelial dysplasia and 
metaplasia.S A considerable amount of epidemio- 
logic data suggests that normal serum vitamin A 
levels protect against he development of epithe- 
lial malignancies2 The development of syn- 
thetic retinoids with minimal hepatic toxicity has 
led to extensive discussions concerning pharma- 
cologic intervention in man in the chemopreven- 
tive mode. 1° What has not been adequately ap- 
preciated in these debates is the differences be- 
tween primary, secondary, and tertiary prevention 
(Table I), Clearly, primary prevention may require 
only dietary supplementation with vitamin A, in 
most cases without active pharmacologic inter- 
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vention. In contrast, secondary prevention will re- 
quire the administration fpharmacologic doses of 
retinoids. It is also important o distinguish be- 
tween those preneoplastic conditions which an be 
managed by local treatment versus those which 
would require systemic treatment. Examples of 
some preneoplastic states requiring local or sys- 
temic approaches are summarized in Table II. A 
carefully conducted investigation of retinoids as 
an antipromoter in the prevention of either oral, 
bladder, or cervical cancer could serve as a model 
for the use of retinoids against preneoplasia in 
humans. The regional administration of retinoids 
to the bladder or oral mucosa would be restricted 
to short-term administration due to the inability to 
conveniently deliver the compound under study 
continuously via local means. In contrast, local 
retinoid applications to the cervix via a mechanical 
delivery system should be possible (vide infra). 
To administer a chemopreventive agent effec- 
tively to patients with cervical preneoplasia, sev- 
eral problems must be addressed: (1) choice of 
agent, (2) delivery of retinoid, (3) local and 
systemic toxicity of the compound, and (4) effec- 
tiveness. The choice of retinoid cannot be easily 
extrapolated from animal investigations since the 
results in preclinical studies are based on investi- 
gations of preneoplastic lesions of diverse his- 
tologic subtypes 11 and, furthermore, no animal 
model for cervical preneoplasia exists. We have 
selected tretinoin for several reasons: this retinoid 
has been used for many years for local control of 
acne, and a considerable amount of information is
available regarding local skin and oral mucosa tox- 
icity. ~z Additionally, well-defined liquid, gel, and 
cream vehicles are available. 
The means of delivery to the cervix is critical 
since it is clear from animal studies that frequent, 
constant, and probably long-term application of 
the retinoid will be required to effect suppression 
of preneoplasia. Dr. Milos Chvapil, at the Uni- 
veristy of Arizona, developed a diaphragm lined 
with a collagen sponge which serves as a vehicle 
for the constant delivery of drugs to the cervix.la 
Using this delivery system, we will deliver treti- 
noin for a total of 4 days with daily replacement. 
In the initial studies, evaluation of toxicity will be 
important. We have therefore designed careful 
Table I, Types of chemoprevention 
Type I Example 
Primary 
Secondary 
Tertiary 
Vitamin A deficiency 
Selenium deficiency 
Cervical dysplasia 
Squamous metaplasia of lung 
"Surgically cured" tumor 
Table II. Secondary prevention in preneoplasias 
Local control 
Cervical dysplasia 
Oral leukoplakia 
Bladder dysplasia 
Lung dysplasia 
Systemic ontrol 
Genetic syndromes 
Preleukemia 
criteria for toxicity, and escalation to the next dos- 
age level will be done systematically. Our pilot 
investigations uggest that upper vaginal wall 
rather than cervical toxicity will be the dose- 
limiting side effect. Efficacy has not yet been de- 
termined. These studies will provide guidelines 
and have important implications for secondary 
prevention of other neoplasms. 
Adjuvant treatment of stage I and stage II 
melanoma with oral vitamin A palmitate 
The suppression or ablation of residual malig- 
nant disease after surgical or radiation therapy can 
be viewed as either prevention of recurrence or 
treatment of residual malignant cells. The treat- 
ment of recurrent melanoma is poor at best, and 
therefore considerable attention has been focused 
on adjuvant reatment, particularly with BCG and 
other immunomodulating a ents. For a variety of 
reasons detailed elsewhere, 14we initiated a strat- 
ified randomized study of BCG __+ high-dose vi- 
tamin A in stage I and stage II malignant mela- 
noma in April, 1978. Patients with histologically 
proved stage I and stage II melanoma were eligi- 
ble. They were stratified by age, sex, and stage 
and randomized equally to receive either weekly 
Connaught BCG by scarification or BCG plus 
100,000 units of vitamin A per day orally for a 
total of 18 months. Although the investigation has 
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not yet matured, an evaluation of the first forty- 
nine patients on study for at least 6 months has 
revealed that: 
1. The relapse rate (6/21 in BCG group) (4/29 in 
BCG + vitamin A group) and pattern of recur- 
rence (distant relapses in two of six patients on 
BCG, but 0 of 4 in BCG + vitamin A group) 
may indicate an advantage to patients receiving 
vitamin A. The difference in relapse-free survival 
in the two groups was not yet statistically sig- 
nificant (p = 0.27) but was encouraging since 
theoretically vitamin A, functioning as a hor- 
mone, may have been expected to induce mela- 
noma growth. 
2. Vitamin A was well tolerated and no evidence of 
liver damage was detected, as assessed by serial 
physical examinations, liver function studies, and 
liver scans. 
Topical vitamin A acid for cutaneous 
malignant melanoma 
Other investigations have demonstrated that 
application of tretinoin to squamous epithelial 
malignancies of the skin frequently resulted in re- 
gression. 7 We recently had the opportunity of 
treating two patients with cutaneous metastatic 
melanoma. ~ The patients were instructed to apply 
one drop of tretinoin (0.05% Retin-A solution) to 
each lesion once a day, and then the lesion was 
covered with occlusive tape. In one patient, com- 
plete clinical and histologic regression of twenty- 
one cutaneous lesions 0.5 to 1.0 cm in diameter 
was obtained. The patient remained free of disease 
for over 18 months from the start of therapy and 
for 12 months after the discontinuation of all ther- 
apy. He subsequently underwent relapse, with 
subcutaneous nodules in the previously diseased 
area. In the second patient, only two of twenty- 
two lesions responded clinically, and epidermal 
necrosis with acute inflammation with residual 
malignant cells was noted. The mechanisms pro- 
ducing these cellular responses to vitamin A acid 
are unknown, but these preliminary studies sug- 
gested that retinoids should be further examined 
for antitumor activity. 
Antitumor activity of isotretinoin 
Retinoids have classically been viewed as 
chemopreventive rather than as treatment modali- 
ties. However, retinoids clearly can inhibit malig- 
nant ceils in culture ~ as well as inhibit human 
tumor stem cells TM in a system which has been 
shown to be clinically predictive. 17 We therefore 
initiated a broad phase II anticancer trim of oral 
isotretinoin (3 mg/kg daily). The detailed results 
are presented elsewhere is and are summarized 
here. No activity was found against nonepithelial 
malignancies (0/21 cases), nor against nonsqua- 
mous epithelial cancers (one response in forty-five 
patients). One of thirteen patients with metastatic 
melanoma responded. In six of twenty-four pa- 
tients with advanced squamous epithelial malig- 
nancies subcutaneous and skin disease sites re- 
sponded. Remarkably, no bone marrow depression 
was seen, and skin toxicity was the limiting side 
effect. 
These preliminary esults give considerable im- 
petus to further investigate the activity of isotreti- 
noin and other retinoids against squamous epithe- 
lial malignancies and give merit to their utilization 
in the chemopreventive s tting. 
Future explorations of retinoids against 
advanced cancer 
To utilize retinoids effectively as chemopre- 
ventive and/or therapeutic agents, several major 
avenues of investigations should be pursued: 
1. What is the best way to deliver etinoids or other 
antipromoters? What is the safest solvent system? 
A large number of studies uggest that low doses 
of retinoids usually are antipromoters, but if 
given at high doses or with certain solvents, pro- 
motion may be dominant.* 
2. What are the mechanisms by which the anti- 
cancer effect is achieved? Is it mmunologic, 
membrane-mediated, via cellular retinoid acid 
binding protein? 
3, What is the range of activity of retinoids in man? 
The recent availability of an in vitro assay system 
which predicts clinical efficacy with high accu- 
racy for cytotoxic drugs may have a useful role in 
the screening ofretinoids 16,t~ and should ecrease 
the amount of time and effort required to identify 
anticancer activity. 
4. Can retinoids potentiate cytotoxic or hormonal 
drug action? Investigation ofthis neglected area is 
*Slaga T: Personal communication, 
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needed, particularly since a few studies suggest 
potential synergisms. 
Our exploration of retinoids as chemopreventive 
and treatment modalities is clearly in its infancy. 
These compounds represent one of the more well- 
defined areas of  biologic modifiers, and an under- 
standing of the mechanisms of action and clinical 
efficacy of retinoids hould provide important clues 
to the noncytotoxic control of cancer. 
A large number of colleagues are involved in these 
investigations, including Drs. D. A[berts, M. Chvapil, 
R. Dorr, W. Droegemueller, N. Levine, E. Surwit, and 
E. Gilmartin, R.N. 
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